Copyright
©The Author(s) 2018.
World J Gastroenterol. Nov 21, 2018; 24(43): 4862-4869
Published online Nov 21, 2018. doi: 10.3748/wjg.v24.i43.4862
Published online Nov 21, 2018. doi: 10.3748/wjg.v24.i43.4862
Table 2 Cryotherapy in esophageal cancer
Author (yr) | No. of patients | Cryotherapy system used | Results | Adverse events |
Cryotherapy in EAC | ||||
Greenwald et al[29] (2010) | 79 (49 completed the treatment) | Low-pressure liquid nitrogen (< 5 psi) cryotherapy system | CE-D in 32%. | Benign strictures (12.6%), pain post treatment (25.3%) |
Tsai et al[30] (2017) | 88 | Low-pressure liquid nitrogen (< 5 psi) cryotherapy system | CE of intraluminal disease in 76.3% T1a, 45.8% T1b, 66.2% T1, and 6.7% T2 | Abdominal pain (19.3%), dysphagia (10.2%), sore throat (9%), and chest pain (8%) |
Kachaamy et al[32] (2018) | 49 | Low-pressure liquid nitrogen system (CryoSpray Ablation System; CSA Medical, Inc, Lexington, Mass) | Improvement in mean dysphagia score | 2% (1) developed a severe intra-procedural perforation, 2% (1) developed a benign stricture requiring dilation. |
Cryotherapy in SCC | ||||
Cash et al[33] (2007) | 1 | Liquid nitrogen cryospray ablation | 100% CE-D | Stricture development |
Canto et al[34] (2018) | 10 | Nitrous oxide (CbFAS) | 100% CE-D in LGIN, HGIN, SCC | Post-procedure pain (40%), esophageal stricture (20%) |
- Citation: Lal P, Thota PN. Cryotherapy in the management of premalignant and malignant conditions of the esophagus. World J Gastroenterol 2018; 24(43): 4862-4869
- URL: https://www.wjgnet.com/1007-9327/full/v24/i43/4862.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i43.4862